Provided by Tiger Trade Technology Pte. Ltd.

Tourmaline Bio

47.98
0.0000
Volume:- -
Turnover:37.61M
Market Cap:1.24B
PE:-13.97
High:47.98
Open:47.98
Low:47.98
Close:47.98
52wk High:48.27
52wk Low:11.56
Shares:25.76M
Float Shares:13.12M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4351
EPS(LYR):-2.8882
ROE:-29.62%
ROA:-20.85%
PB:4.77
PE(LYR):-16.61

Loading ...

Tourmaline Bio (TRML): Evaluating Valuation After Recent Strong Share Price Gains

Simply Wall St.
·
Oct 29, 2025

Tourmaline Bio Inc. Files Initial Beneficial Ownership Statement Naming Novartis AG

Reuters
·
Oct 29, 2025

Tourmaline Bio to Delist from Nasdaq and Deregister

TIPRANKS
·
Oct 28, 2025

Tourmaline Bio Inc. Completes Merger and Terminates $100 Million ATM Sales Agreement

Reuters
·
Oct 28, 2025

Tourmaline Bio acquisition completed by Novartis

TIPRANKS
·
Oct 28, 2025

Novartis Ag - With Completion of Acquisition, Shares of Common Stock, Par Value $0.0001 per Share ( "Shares")

THOMSON REUTERS
·
Oct 28, 2025

BRIEF-Novartis Announces Expiration Of Tourmaline Bio Tender Offer

Reuters
·
Oct 28, 2025

Tourmaline Bio’s Promising Phase 2b Study on Thyroid Eye Disease Treatment

TIPRANKS
·
Oct 28, 2025

Novartis announces expiration of HSR Act waiting period of Tourmaline Bio offer

TIPRANKS
·
Oct 22, 2025

Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer

GlobeNewswire
·
Oct 22, 2025

Novartis Ag - Torino Merger Sub Inc Commenced a Tender Offer to Acquire All of Outstanding Shares of Common Stock, Par Value $0.0001 per Share of Tourmaline Bio, Inc at a Price of $48 per Share, in Cash, Without Interest

THOMSON REUTERS
·
Sep 29, 2025

Novartis Ag - Offer Will Expire at One Minute Following 11:59 P.m., New York City Time, on October 27, 2025, Unless Offer Is Otherwise Extended

THOMSON REUTERS
·
Sep 29, 2025

Novartis announces commencement of tender offer to acquire Tourmaline Bio

GlobeNewswire
·
Sep 29, 2025

BMO Capital Downgrades Tourmaline Bio to Market Perform From Outperform, Raises Price Target to $48 From $35

MT Newswires Live
·
Sep 15, 2025

Tourmaline Bio Cut to Market Perform From Outperform by BMO Capital

Dow Jones
·
Sep 15, 2025

Hold Rating Issued Amid Novartis’ Acquisition of Tourmaline Bio

TIPRANKS
·
Sep 15, 2025

Tourmaline Bio Inc. Announces New Executive Severance and Change in Control Plan with Enhanced Compensation Terms

Reuters
·
Sep 13, 2025

Tourmaline Bio Cut to Neutral From Overweight by Piper Sandler

Dow Jones
·
Sep 12, 2025

Piper Sandler Downgrades Tourmaline Bio to Neutral From Overweight, Lowers Price Target to $48 From $65

MT Newswires Live
·
Sep 11, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Potbelly, Joby, Talen Energy

Reuters
·
Sep 11, 2025